| Market Cap | 13.52B | P/E | - | EPS this Y | 56.10% | Ern Qtrly Grth | - |
| Income | -285.01M | Forward P/E | -31.12 | EPS next Y | 40.30% | 50D Avg Chg | 7.00% |
| Sales | 455.99M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 32.00% |
| Dividend | N/A | Price/Book | 18.97 | EPS next 5Y | - | 52W High Chg | -3.00% |
| Recommedations | 1.80 | Quick Ratio | 4.73 | Shares Outstanding | 184.29M | 52W Low Chg | 101.00% |
| Insider Own | 1.30% | ROA | -12.52% | Shares Float | 162.15M | Beta | 0.11 |
| Inst Own | 51.29% | ROE | -22.21% | Shares Shorted/Prior | 10.47M/10.71M | Price | 74.99 |
| Gross Margin | -30.76% | Profit Margin | -62.50% | Avg. Volume | 702,648 | Target Price | 82.99 |
| Oper. Margin | -22.50% | Earnings Date | Nov 18 | Volume | 322,630 | Change | 0.50% |
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.